<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354015</url>
  </required_header>
  <id_info>
    <org_study_id>1-Fonseca</org_study_id>
    <nct_id>NCT01354015</nct_id>
  </id_info>
  <brief_title>Diabetes Remote Care Management System</brief_title>
  <acronym>DRMS</acronym>
  <official_title>Diabetes Remote Care Management System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DRMS is a system that communicates with patients via text message using cellphones, computers&#xD;
      and other devices. It reminds patients about multiple health care and disease related issues&#xD;
      such as to test their blood sugars and send the result back to the system via text message.&#xD;
      The system will then decided based on automated algorithms whether to send another message&#xD;
      advising patients on changing their medication etc.&#xD;
&#xD;
      This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type 1&#xD;
      and Type 2 diabetes mellitus, using insulin, who will be enrolled to participate in the&#xD;
      pilot. Patients will be randomized 1:1 to either DRMS or standard care. The patients in the&#xD;
      DRMS program will undergo interactions with the system using multiple communications channels&#xD;
      including cell phones, IVR, email, web and SMS messaging. The goals of the interactive&#xD;
      programs are the following:&#xD;
&#xD;
        1. Monitor and intervene to remind patients to fill their prescriptions&#xD;
&#xD;
        2. Monitor and track insulin unit consumption utilization and timing of that dosage&#xD;
&#xD;
        3. Monitor and intervene when the patient does not use or take their medications as&#xD;
           prescribed.&#xD;
&#xD;
        4. Monitor and track insulin unit consumption and timing of that dosage&#xD;
&#xD;
        5. Ask the patient for their glucose levels and then provide customized information to the&#xD;
           patients regarding how to modify their medication to achieve the desired glucose level&#xD;
&#xD;
        6. Deliver automated dose adjustment directions based on the providers instructions&#xD;
&#xD;
        7. Coordinate personalized educational programs and messages into the automated&#xD;
           intervention programs&#xD;
&#xD;
        8. Provide feedback to the patients, including performance and reinforcement to both&#xD;
           providers and to patients.&#xD;
&#xD;
        9. Provide feedback to providers on patients performance as well as exception based&#xD;
           reporting&#xD;
&#xD;
      The System will manage interventions in an automated fashion. Providers will intervene on an&#xD;
      exception basis and only when automated interventions have not worked or the protocol&#xD;
      requires immediate action by the provider. For example, if the glucose exceeds certain danger&#xD;
      levels, as defined by the provider, a requirement might be to call and notify the doctor&#xD;
      immediately.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To determine the feasibility of using cell and phone technology to monitor,&#xD;
      intervene and manage diabetes in patients using insulin.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      1.To determine whether the DRMS system leads to improved glucose control (as measured by&#xD;
      HgA1cHbA1c) during participation in the pilot&#xD;
&#xD;
      .2.To determine whether the DRMS system leads to improved management and adherence to insulin&#xD;
      as well as other diabetic medications .3.To determine whether the DRMS system can be used as&#xD;
      a cost effective solution for interventions across a broad segment (both demographic and&#xD;
      economic groups) of the diabetes population.&#xD;
&#xD;
      This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type I1&#xD;
      and Type II2 diabetes mellitus, using insulin, who will be enrolled to participate in the&#xD;
      pilot. Patients will be randomized 1:1 to either DRMS or standard care. It is anticipated&#xD;
      that 150 patients will be screened in order to enroll 100 patients in the clinical trial. The&#xD;
      patients in the DRMS program will undergo interactions with the system using multiple&#xD;
      communications channels including cell phones, IVR, email, web and SMS messaging. The goals&#xD;
      of the interactive programs are the following:&#xD;
&#xD;
        1. Monitor and intervene to remind patients to fill their prescriptions&#xD;
&#xD;
        2. Monitor and track insulin unit consumption utilization and timing of that dosage&#xD;
&#xD;
        3. Monitor and intervene when the patient does not use or take their medications as&#xD;
           prescribed.&#xD;
&#xD;
        4. Monitor and track insulin unit consumption and timing of that dosage&#xD;
&#xD;
        5. Ask the patient for their glucose levels and then provide customized information to the&#xD;
           patients regarding how to modify their medication to achieve the desired glucose level&#xD;
&#xD;
        6. Deliver automated titration directions based on the providers instructions&#xD;
&#xD;
        7. Coordinate personalized educational programs and messages into the automated&#xD;
           intervention programs&#xD;
&#xD;
        8. Provide feedback to the patients, including performance and reinforcement to both&#xD;
           providers and to patients.&#xD;
&#xD;
        9. Provide feedback to providers on patients performance as well as exception based&#xD;
           reporting&#xD;
&#xD;
      The System will manage interventions in an automated fashion. Providers will intervene on an&#xD;
      exception basis and only when automated interventions have not worked or the protocol&#xD;
      requires immediate action by the provider. For example, if the glucose exceeds certain danger&#xD;
      levels, as defined by the provider, a requirement might be to call and notify the doctor&#xD;
      immediately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>change in A1c from baseline in intervention and control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c Over 3 Months</measure>
    <time_frame>baseline to 3 months</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Use of messaging system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of DRMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DRMS</intervention_name>
    <description>USE OF TEXT MESSAGING SYSTEM</description>
    <arm_group_label>Use of messaging system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Able to read and understand the ICF and provide written consent.&#xD;
&#xD;
          3. Diagnosis of Type 1 or Type 2 diabetes. If Type 1 diabetes, requirement that they be&#xD;
             on insulin and if Type 2 diabetes, requirement that they be on r insulin.&#xD;
&#xD;
          4. Recent HbA1c blood test (within the last 30 days).&#xD;
&#xD;
          5. An HbA1c reading of 7.5% - 9.0%.&#xD;
&#xD;
          6. Patient must own or have access to cell phone on a daily basis throughout the study&#xD;
             period, and optionally can have a conventional phone or access to the Internet.&#xD;
&#xD;
          7. Patient possesses a blood sugar monitor and has access to supplies.&#xD;
&#xD;
          8. Patient is felt to be able to be compliant with the study.&#xD;
&#xD;
          9. Patient has no plans to move over the 6 month period of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have active cancer other than basal cell carcinoma or cervical or breast cancer in&#xD;
             situ.&#xD;
&#xD;
          2. In the opinion of the investigator are not suitable for entry into the study.&#xD;
&#xD;
          3. History of any psychiatric or neurologic condition that might impair the patient's&#xD;
             ability to understand or to comply with the requirements of the study or to provide&#xD;
             informed consent&#xD;
&#xD;
          4. Pregnant or breast-feeding females.&#xD;
&#xD;
          5. History (within last 6 months) of significant cardiovascular disease unless the&#xD;
             disease is well-controlled. Significant cardiac diseases includes second/third degree&#xD;
             heart block; clinically significant ischemic heart disease; QTcF interval &gt; 450 msec&#xD;
             at screening; poorly controlled hypertension; congestive heart failure of New York&#xD;
             Heart Association (NYHA) Class II or worse (slight limitation of physical activity;&#xD;
             comfortable at rest, but ordinary physical activity results in fatigue, palpitation,&#xD;
             or dyspnea) or uncontrolled cardiac arrhythmias.&#xD;
&#xD;
          6. History of cerebrovascular accident (CVA) within 6 months prior to randomization or&#xD;
             that resulted in ongoing neurologic instability.&#xD;
&#xD;
          7. Active infection or serious underlying medical condition (including any type of active&#xD;
             seizure disorder within 12 months prior to randomization) that would impair the&#xD;
             ability of the patient to participate in the trial.&#xD;
&#xD;
          8. Hypoglycemia Unawareness&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Fonseca</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 6, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <results_first_submitted>December 30, 2014</results_first_submitted>
  <results_first_submitted_qc>January 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2015</results_first_posted>
  <last_update_submitted>March 25, 2017</last_update_submitted>
  <last_update_submitted_qc>March 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Medicine</investigator_affiliation>
    <investigator_full_name>Vivian Fonseca</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Technology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>01/01/12 from diabetes clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS&#xD;
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS&#xD;
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="10.3"/>
                    <measurement group_id="B2" value="59.3" spread="8.7"/>
                    <measurement group_id="B3" value="59.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>self reported</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c</title>
        <description>change in A1c from baseline in intervention and control groups</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Of the 50 enrolled in the Use of DRMS group, only 44 completed the visit at 6 months, and out of 48 enrolled in the Usual Care group only 43 completed the visit at 6 months. Therefore only those who completed the visit at 6 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Use of Messaging System</title>
            <description>Use of DRMS&#xD;
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c</title>
          <description>change in A1c from baseline in intervention and control groups</description>
          <population>Of the 50 enrolled in the Use of DRMS group, only 44 completed the visit at 6 months, and out of 48 enrolled in the Usual Care group only 43 completed the visit at 6 months. Therefore only those who completed the visit at 6 months were included in this analysis.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>All statistical analysis used intent-to-treat methodology and all comparisons used a two-tailed test at the .05 level of significance. Continuous variables are reported as means and standard deviations. W</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2539</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c Over 3 Months</title>
        <description>Change in HbA1c</description>
        <time_frame>baseline to 3 months</time_frame>
        <population>Of the 50 enrolled in the Use of DRMS group, only 46 completed the visit at 3 months, and out of 48 enrolled in the Usual Care group only 45 completed the visit at 3 months. Therefore only those who completed the visit at 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Use of Messaging System</title>
            <description>Use of DRMS&#xD;
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Over 3 Months</title>
          <description>Change in HbA1c</description>
          <population>Of the 50 enrolled in the Use of DRMS group, only 46 completed the visit at 3 months, and out of 48 enrolled in the Usual Care group only 45 completed the visit at 3 months. Therefore only those who completed the visit at 3 months were included in this analysis.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.3"/>
                    <measurement group_id="O2" value="-0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS&#xD;
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Vivian Fonseca</name_or_title>
      <organization>Tulane University</organization>
      <phone>5049884026</phone>
      <email>vfonseca@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

